(Q34492626)

2 August 2017

1 reference

title

Tamsulosin: an update of its role in the management of lower urinary tract symptoms (English)

1 reference

2 August 2017

3

Antona J Wagstaff

1 reference

Katherine A Lyseng-Williamson

2 August 2017

series ordinal

1

object named as

Katherine A Lyseng-Williamson

1 reference

2 August 2017

Blair Jarvis

2

1 reference

2 August 2017

language of work or name

1 reference

1 January 2002

1 reference

2 August 2017

1 reference

2 August 2017

volume

62

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

135-167

1 reference

Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group

2 August 2017

cites work

1 reference

12 December 2020

Comprehensive patient evaluation for benign prostatic hyperplasia

1 reference

12 December 2020

Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience

1 reference

12 December 2020

Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group

1 reference

12 December 2020

Tamsulosin in men with confirmed bladder outlet obstruction: a clinical and urodynamic analysis from a single centre in New Zealand

1 reference

12 December 2020

High prevalence of benign prostatic hypertrophy in the community

1 reference

12 December 2020

Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia.

1 reference

12 December 2020

Urinary symptoms in the community: how bothersome are they?

1 reference

12 December 2020

Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate

1 reference

12 December 2020

Alpha-1 adrenoceptor antagonist effects of the optical isomers of YM-12617 in rabbit lower urinary tract and prostate

1 reference

12 December 2020

Disposition of the selective alpha1A-adrenoceptor antagonist tamsulosin in humans: comparison with data from interspecies scaling

1 reference

12 December 2020

Alpha1-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha1-adrenergic receptor subtypes at four distinct levels

1 reference

12 December 2020

Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia

1 reference

12 December 2020

3-year followup of urinary symptoms after transurethral resection of the prostate

1 reference

12 December 2020

Management of symptomatic BPH in the US: who is treated and how?

1 reference

12 December 2020

Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study.

1 reference

12 December 2020

Comparison of cloned and pharmacologically defined rat tissue alpha 1-adrenoceptor subtypes.

1 reference

12 December 2020

Effects of the concomitant administration of tamsulosin (0.8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin) in normal healthy subjects: a placebo-controlled evaluation

1 reference

12 December 2020

Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability?

1 reference

12 December 2020

Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy

1 reference

12 December 2020

Review of orthostatic tests on the safety of tamsulosin, a selective alpha1A-adrenergic receptor antagonist, shows lack of orthostatic hypotensive effects

1 reference

12 December 2020

alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.

1 reference

12 December 2020

Benign prostatic hyperplasia. Practical treatment guidelines

1 reference

12 December 2020

Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group

1 reference

12 December 2020

International comparison of the community prevalence of symptoms of prostatism in four countries.

1 reference

12 December 2020

The International Continence Society "Benign Prostatic Hyperplasia" Study: the botherosomeness of urinary symptoms

1 reference

12 December 2020

Obstructive uropathy in the male

1 reference

12 December 2020

Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia

1 reference

12 December 2020

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

1 reference

12 December 2020

Clinical manifestations of benign prostatic hyperplasia.

1 reference

12 December 2020

The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes

1 reference

12 December 2020

International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update.

1 reference

12 December 2020

Temporal resolution of urinary morbidity following prostate brachytherapy

1 reference

12 December 2020

Do we know everything about alpha-blockade in the management of lower urinary tract symptoms?

1 reference

12 December 2020

Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect

1 reference

12 December 2020

Pharmacologic therapy for prostatism

1 reference

12 December 2020

Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: interactions with antihypertensive therapy

1 reference

12 December 2020

Alpha1-adrenergic receptor subtypes in human detrusor

1 reference

12 December 2020

Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans

1 reference

12 December 2020

Comparative study on alpha 1-adrenoceptor antagonist binding in human prostate and aorta

1 reference

12 December 2020

Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms

1 reference

12 December 2020

Relationship of Symptoms of Prostatism to Commonly Used Physiological and Anatomical Measures of the Severity of Benign Prostatic Hyperplasia

1 reference

12 December 2020

The pharmacovigilance of tamsulosin: event data on 12484 patients

1 reference

12 December 2020

Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer.

1 reference

12 December 2020

A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group

1 reference

12 December 2020

Symptom status and quality of life following prostatectomy.

1 reference

12 December 2020

Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group

1 reference

12 December 2020

Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia

1 reference

12 December 2020

Does the time of administration (morning or evening) affect the tolerability or efficacy of tamsulosin?

1 reference

12 December 2020

Tamsulosin : A Review of its Pharmacological Properties and Therapeutic Potential in the Management of Symptomatic Benign Prostatic Hyperplasia

1 reference

12 December 2020

Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Europe

1 reference

12 December 2020

A comparison of the antagonistic activities of tamsulosin and terazosin against human vascular alpha1-adrenoceptors

1 reference

12 December 2020

Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes

1 reference

12 December 2020

Identification, Quantification, and Localization of mRNA for Three Distinct Alpha1Adrenergic Receptor Subtypes in Human Prostate

1 reference

12 December 2020

Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma

1 reference

12 December 2020

Effect of the optical isomers of YM-12617 on increased intra-urethral pressure induced by phenylephrine in anaesthetized dogs

1 reference

12 December 2020

BPH: new guidelines based on symptoms and patient preference. The Agency for Health Care Policy and Research

1 reference

12 December 2020

A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia)

1 reference

12 December 2020

Tamsulosin: real life clinical experience in 19,365 patients

1 reference

12 December 2020

Alpha 1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Evidence for heterogeneity of chloroethylclonidine-resistant rat renal alpha 1-adrenoceptor

1 reference

12 December 2020

Absorption, metabolism and excretion of tamsulosin hydrochloride in man

1 reference

12 December 2020

Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist

1 reference

12 December 2020

Benign prostatic hyperplasia: an overview

1 reference

12 December 2020

Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin

1 reference

12 December 2020

Ex vivo occupancy by tamsulosin of alpha1-adrenoceptors in rat tissues in relation to the plasma concentration

1 reference

12 December 2020

Ultrasonic estimation of bladder weight as a measure of bladder hypertrophy in men with infravesical obstruction: a preliminary report

1 reference

12 December 2020

Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia

1 reference

12 December 2020

Medical Management of Benign Prostatic Hyperplasia: A Canine Model Comparing the in Vivo Efficacy of Alpha-1 Adrenergic Antagonists in the Prostate

1 reference

12 December 2020

International Consultation on Urological Diseases: a decade of progress

1 reference

12 December 2020

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

12 December 2020

Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group

1 reference

12 December 2020

alpha(1)-blockers for BPH: are there differences?

1 reference

12 December 2020

Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study G

1 reference

12 December 2020

Use of an alpha 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. YM617 Clinical Study Group

1 reference

12 December 2020

Alpha-adrenergic blocking drugs in bladder outflow obstruction: what potential has alpha 1-adrenoceptor selectivity?

1 reference

12 December 2020

Novel role for alpha1-adrenergic receptor subtypes in lower urinary tract symptoms

1 reference

12 December 2020

Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. The Kobe University YM617 Study Group

1 reference

12 December 2020

Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: results of a pilot study

1 reference

12 December 2020

alpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression.

1 reference

12 December 2020

Benign prostatic hyperplasia: use of drug therapy in primary care

1 reference

12 December 2020

Mode of action of alpha1-adrenoreceptor antagonists in the treatment of lower urinary tract symptoms

1 reference

12 December 2020

Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes

1 reference

12 December 2020

Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

1 reference

12 December 2020

How do symptoms indicative of BPH progress in real life practice? The UK experience

1 reference

12 December 2020

A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing

1 reference

12 December 2020

Recent advances in the identification of alpha1- and alpha2-adrenoceptor subtypes: therapeutic implications.

1 reference

12 December 2020

Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group

1 reference

12 December 2020

Transurethral prostatectomy: practice aspects of the dominant operation in American urology

1 reference

12 December 2020

Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics

1 reference

12 December 2020

Worldwide experience with alfuzosin and tamsulosin

1 reference

12 December 2020

Alpha 1-adrenoceptor subtype selectivity of tamsulosin: studies using livers from different species

1 reference

12 December 2020

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

12 December 2020

Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate.

1 reference

12 December 2020

The prevalence of prostatism: a population-based survey of urinary symptoms

1 reference

12 December 2020

Finasteride and tamsulosin used in benign prostatic hypertrophy: a review of the prescription-event monitoring data

1 reference

12 December 2020

Noninvasive quantitative estimation of infravesical obstruction using ultrasonic measurement of bladder weight

1 reference

12 December 2020

Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.

1 reference

12 December 2020

A 6-month large-scale study into the safety of tamsulosin

1 reference

12 December 2020

Alpha blockers: are all created equal?

1 reference

12 December 2020

Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses.

1 reference

12 December 2020

Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of the antagonistic activity of tamsulosin and doxazosin at vascular alpha 1-adrenoceptors in humans

1 reference

12 December 2020

Antagonistic activity of tamsulosin against human vascular alpha1-adrenergic receptors

1 reference

12 December 2020

In vivo measurement by [3H]Tamsulosin of alpha1 adrenoceptors in rat tissues in relation to the pharmacokinetics

1 reference

12 December 2020

Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age.

1 reference

12 December 2020

Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.

1 reference

12 December 2020

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

Alpha-blockers and lower urinary tract function: more than smooth muscle relaxation?

1 reference

12 December 2020

Alpha1-blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the relevant differences in randomised controlled trials?

1 reference

12 December 2020

Effects of the concomitant administration of tamsulosin (0.8 mg/day) on the pharmacokinetic and safety profile of theophylline (5 mg/kg): a placebo-controlled evaluation

1 reference

12 December 2020

The Agency for Health Care Policy and Research. Clinical guidelines for the diagnosis and treatment of benign prostatic hyperplasia.

1 reference

12 December 2020

Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes

1 reference

12 December 2020

A comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH.

1 reference

12 December 2020

10.2165/00003495-200262010-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1023824532

0 references

1 reference